Search Result

Results for "

ROS1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Anaplastic lymphoma kinase (ALK) (23) Apoptosis (13) Autophagy (10) Bacterial (1) Bcl-2 Family (1) BCRP (1) c-Met/HGFR (9) Caspase (1) Cholinesterase (ChE) (1) Discoidin Domain Receptor (2) EGFR (2) Endogenous Metabolite (3) ERK (2) FAK (2) Ferroptosis (1) FKBP (1) FLT3 (2) Fungal (2) Isotope-Labeled Compounds (3) JNK (1) NAMPT (1) p38 MAPK (2) PPAR (1) PROTACs (1) Reactive Oxygen Species (21) ROS Kinase (32) Sigma Receptor (1) Small Interfering RNA (siRNA) (3) STAT (1) TAM Receptor (1) Trk Receptor (6) VEGFR (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (46) Infection (4) Inflammation/Immunology (6) Metabolic Disease (3) Neurological Disease (2)
Click Chemistry:	Azide (1)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-152292

Zidesamtinib NVL-520; NUV-520	ROS Kinase	Cancer
Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC₅₀s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer ^[1].

HY-RS12135

ROS1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ROS1 Human Pre-designed siRNA Set A contains three designed siRNAs for ROS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ROS1 Human Pre-designed siRNA Set A ROS1 Human Pre-designed siRNA Set A

HY-RS12136

Ros1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ros1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ros1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ros1 Mouse Pre-designed siRNA Set A Ros1 Mouse Pre-designed siRNA Set A

HY-RS12137

ROS1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ROS1 Rat Pre-designed siRNA Set A contains three designed siRNAs for ROS1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

ROS1 Rat Pre-designed siRNA Set A ROS1 Rat Pre-designed siRNA Set A

HY-161975

ROS1-IN-2	ROS Kinase	Cancer
ROS1-IN-2 (Compound 3) is a *ROS1* inhibitor. ROS1-IN-2 can be used in the study of cancer ^[1].

HY-150974

ROS1-IN-1	ROS Kinase	Cancer
ROS1-IN-1 (Compound 31) is a potent and selective *ROS1* kinase inhibitor with an IC₅₀ of 0.097 μM ^[1].

HY-157391

*ALK/ROS1-IN-3*	ROS Kinase Anaplastic lymphoma kinase (ALK)	Cancer
ALK/ROS1-IN-3 (compound C01) is a *ROS1* and ALK dual inhibitor with IC₅₀s of 42.3 nM and 49.1 nM for ROS1 ^G2032R and ALK ^G1202R, respectively ^[1].

HY-160172

*ALK/ROS1-IN-4*	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
ALK/ROS1-IN-4 (example 13) is a dual inhibitor of ALK and ROS1 kinase ^[1].

HY-160172A

*ALK/ROS1-IN-4 hydrate*	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
ALK/ROS1-IN-4 (hydrate) (example 13) is a dual inhibitor of ALK and ROS1 kinase ^[1].

HY-130794

*ALK/ROS1-IN-1*	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
ALK/ROS1-IN-1 (compound 2e) is a potent and selective anti crizotinib-resistant *ALK/ROS1* dual inhibitor, with IC₅₀s of 0.174 μM and 0.530 μM for ALK and ROS1 enzyme, respectively.

HY-153743

Protein kinase inhibitor 4	ROS Kinase Trk Receptor	Cancer
Protein kinase inhibitor 4 (Compound 3) is a protein kinase inhibitor that inhibits TRK-A and *ROS1* (IC₅₀=3.0 nM and 104 nM respectively) ^[1].

HY-159147

SIAIS039	PROTACs ROS Kinase Apoptosis	Cancer
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC₅₀s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) ^[1].

HY-131003

Taletrectinib 1 Publications Verification DS-6051b; AB-106; IBI-344	ROS Kinase	Cancer
Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective *ROS1/NTRK* inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC₅₀s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants ^[1] .

HY-131003A

Taletrectinib free base DS-6051b free base; AB-106 free base; IBI-344 free base	ROS Kinase	Cancer
Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective *ROS1/NTRK* inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC₅₀s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib free base also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants ^[1] .

HY-112801

F-1	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
F-1 is a potent ALK and *ROS1* dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC₅₀s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALK ^WT, ROS1 ^WT, ALK ^L1196M and ALK ^G1202R, respectively ^[1].

HY-111416

WY-135	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
WY-135 is an ALK (IC₅₀=1.4 nM) and *ROS1* (IC₅₀=1.1 nM) dual inhibitor.

HY-12215

Lorlatinib 25+ Cited Publications PF-06463922	Anaplastic lymphoma kinase (ALK) ROS Kinase Apoptosis	Cancer
Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive *ROS1/ALK* inhibitor with anticancer activity. Lorlatinib has K_is of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK ^L1196M, respectively. Lorlatinib targets to EML4-ALK, and inhibits ALK phosphorylation with IC₅₀s of 15-43 nM (ALK ^L1196), 14-80 nM (ALK ^G1269A), 38-50 nM (ALK ^1151Tins), 77-113 nM (ALK ^G1202R), respectively ^[1] .

HY-135509

Lorlatinib acetate PF-06463922 acetate	Anaplastic lymphoma kinase (ALK) ROS Kinase Apoptosis	Cancer
Lorlatinib (PF-06463922) acetate is a selective, orally active, brain-penetrant and ATP-competitive *ROS1/ALK* inhibitor with anticancer activity. Lorlatinib acetate has K_is of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK ^L1196M, respectively. Lorlatinib acetate targets to EML4-ALK, and inhibits ALK phosphorylation with IC₅₀s of 15-43 nM (ALK ^L1196), 14-80 nM (ALK ^G1269A), 38-50 nM (ALK ^1151Tins), 77-113 nM (ALK ^G1202R), respectively ^[1] .

HY-155163

APG-2449	Anaplastic lymphoma kinase (ALK) ROS Kinase FAK	Others Cancer
APG-2449 is an orally active *ALK/ROS1/FAK* inhibitor. APG-2449 shows antitumor activity in mouse models of non-small cell lung cancer (NSCLC) ^[1].

HY-12215R

Lorlatinib (Standard)	Anaplastic lymphoma kinase (ALK) ROS Kinase Apoptosis	Cancer
Lorlatinib (Standard) is the analytical standard of Lorlatinib. This product is intended for research and analytical applications. Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive *ROS1/ALK* inhibitor with anticancer activity. Lorlatinib has K_is of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK ^L1196M, respectively. Lorlatinib targets to EML4-ALK, and inhibits ALK phosphorylation with IC₅₀s of 15-43 nM (ALK ^L1196), 14-80 nM (ALK ^G1269A), 38-50 nM (ALK ^1151Tins), 77-113 nM (ALK ^G1202R), respectively ^[1] .

HY-103022

Repotrectinib 4 Publications Verification TPX-0005	ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK)	Cancer
Repotrectinib (TPX-0005) is a potent *ROS1* (IC₅₀=0.07 nM) and TRK (IC₅₀=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT ALK (IC₅₀=1.01 nM). Repotrectinib has anti-cancer activity ^[1] .

HY-12678

Entrectinib 20+ Cited Publications NMS-E628; RXDX-101	ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy	Cancer
Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, *ROS1* and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice ^[1] .

HY-50878

Crizotinib Maximum Cited Publications 66 Publications Verification PF-02341066	Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase Autophagy	Cancer
Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a *ROS1* inhibitor. Crizotinib has effective tumor growth inhibition ^[1] .

HY-50878B

Crizotinib acetate PF-02341066 acetate	Anaplastic lymphoma kinase (ALK) ROS Kinase c-Met/HGFR	Cancer
Crizotinib (PF-02341066) acetate is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib acetate inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib acetate is also a *ROS1* inhibitor. Crizotinib acetate has effective tumor growth inhibition ^[1] .

HY-145574

Iruplinalkib WX-0593	Anaplastic lymphoma kinase (ALK) ROS Kinase BCRP Akt ERK STAT	Cancer
Iruplinalkib (WX-0593) is an orally active and selective *ALK/ROS1* inhibitor. Iruplinalkib can effectively inhibit tyrosine autophosphorylation of ALK and mutant ALK, EGFR, with the IC₅₀ between 5.38 and 16.74 nM. Iruplinalkib is also a suppressive agent of the transporter *MATE1, MATE2K, P-gp* and BCRP. Iruplinalkib can be used in the study of non-small cell lung cancer ^[1] .

HY-12678R

Entrectinib (Standard)	ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy	Cancer
Entrectinib (Standard) is the analytical standard of Entrectinib. This product is intended for research and analytical applications. Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, *ROS1* and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice ^[1] .

HY-B0847S

Propiconazole-d7	Fungal Reactive Oxygen Species	Infection
Propiconazole-d₇ is the deuterium labeled Propiconazole. Propiconazole is a broad-spectrum triazole fungicide that inhibits the conversion of lanosterol to ergosterol, leading to fungal cell membrane disruption. Propiconazole inhibits S. cerevisiae, but not rat liver, microsomal cytochrome P450 (IC50s=0.04 and >200 µM, respectively). Propiconazole inhibits the growth of T. deformans and R. stolonifer (ED50s=0.073 and 4.6 µg/mL, respectively). Propiconazole increases production of reactive oxygen species (ROS)[1].

HY-50878S

Crizotinib-d5 PF-02341066-d₅	Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase Autophagy	Cancer
Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition ^[1] .

HY-50878R

Crizotinib (Standard)	Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase Autophagy	Cancer
Crizotinib (Standard) is the analytical standard of Crizotinib. This product is intended for research and analytical applications. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a *ROS1* inhibitor. Crizotinib has effective tumor growth inhibition ^[1] .

HY-50878A

Crizotinib hydrochloride Maximum Cited Publications 66 Publications Verification PF-02341066 hydrochloride	Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase Autophagy	Cancer
Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a **ROS proto-oncogene 1 (ROS1)** inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition ^[1] .

HY-120387

SMU-B	ROS Kinase Anaplastic lymphoma kinase (ALK) TAM Receptor c-Met/HGFR	Cancer
SMU-B is the orally active inhibitor for ALK (IC₅₀<0.5 nM), *c-ros* oncogene 1** (ROS1), c-MET (IC₅₀=1.87 nM) and AXL (IC₅₀=28.9 nM). SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC₅₀s of 0.02 μM, 1.58 μM and 2.82 μM, respectively. SMU-B exhibits antitumor efficacy in mouse models ^[1] .

HY-12678S

Entrectinib-d4 NMS-E628-d₄; RXDX-101-d₄	ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy Isotope-Labeled Compounds	Cancer
Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib (HY-12678). Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, *ROS1* and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice ^[1] .

HY-15514A

Merestinib dihydrochloride 5 Publications Verification LY2801653 dihydrochloride	c-Met/HGFR FLT3 ROS Kinase Discoidin Domain Receptor	Cancer
Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (K_i=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC₅₀=11 nM), FLT3 (IC₅₀=7 nM), AXL (IC₅₀=2 nM), MERTK (IC₅₀=10 nM), TEK (IC₅₀=63 nM), ROS1, DDR1/2 (IC₅₀=0.1/7 nM) and MKNK1/2 (IC₅₀=7 nM) ^[1] .

HY-15514

Merestinib 5 Publications Verification LY2801653	c-Met/HGFR FLT3 ROS Kinase Discoidin Domain Receptor	Cancer
Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (K_i=2 nM) with anti-tumor activities. Merestinib (LY2801653) also has potent activity against MST1R (IC₅₀=11 nM), FLT3 (IC₅₀=7 nM), AXL (IC₅₀=2 nM), MERTK (IC₅₀=10 nM), TEK (IC₅₀=63 nM), ROS1, DDR1/2 (IC₅₀=0.1/7 nM) and MKNK1/2 (IC₅₀=7 nM) ^[1] .

HY-50878AS

Crizotinib-d9 hydrochloride PF-02341066-d₉ hydrochloride	c-Met/HGFR Autophagy Anaplastic lymphoma kinase (ALK) ROS Kinase Isotope-Labeled Compounds	Cancer
Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a **ROS proto-oncogene 1 (ROS1)** inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition ^[1] .

HY-12678S1

Entrectinib-d8 NMS-E628-d₈; RXDX-101-d₈	Isotope-Labeled Compounds Autophagy Anaplastic lymphoma kinase (ALK) Trk Receptor ROS Kinase	Cancer
Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC₅₀ values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice ^[1] .

HY-155178

Antiproliferative agent-34	EGFR	Cancer
Antiproliferative agent-34 (Compound A14) is a multi-target kinase inhibitor, with an IC₅₀ of 177 nM and 1567 nM for EGFR L858R/T790M and EGFR WT. Antiproliferative agent-34 also inhibits JAK2, ROS1, FLT3, FLT4, PDGFRα with IC₅₀ of 30.93, 106.90, 108.00, 226.60, 42.53 nM. Antiproliferative agent-34 inhibits H1975 and HCC827 cells proliferation with IC₅₀ values below 40 nM under normoxic condition, and the anti-proliferation potency achieves 4–6-fold improvement (IC₅₀ values < 10 nM) under hypoxic condition ^[1].

HY-123454

SKF1	FKBP Reactive Oxygen Species	Infection
SKF1 is a FK506 suppressor, causes a mitochondrially induced death in low salt, concomitant with the release of reactive oxygen species (ROS) .

HY-N7798

Pennogenin	Reactive Oxygen Species	Inflammation/Immunology
Pennogenin is a bioactive component which can be isolated from T. govanianum rhizomes. Pennogenin exhibits significant in vitro inhibitory effect on release of ROS .

HY-W015913

Sodium 2-oxopropanoate 5+ Cited Publications Sodium pyruvate	Reactive Oxygen Species Endogenous Metabolite	Metabolic Disease
Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

HY-156360

Xanthine oxidase-IN-12	Xanthine Oxidase Reactive Oxygen Species	Inflammation/Immunology
Xanthine oxidase-IN-12 (Compound 11) is a xanthine oxidase (XO) inhibitor with an IC₅₀ of 91 nM. Xanthine oxidase-IN-12 also has antioxidant activity and reduces intracellular ROS .

HY-144697

p38 MAPK-IN-3	p38 MAPK Apoptosis Reactive Oxygen Species	Cancer
p38 MAPK-IN-3 (Compound 2c) is a p38α MAPK inhibitor. p38 MAPK-IN-3 has antitumor activities and induces apoptosis and *ROS* .

HY-N0578

Apigenin 7-glucoside 3 Publications Verification Apigenin-7-O-β-D-glucopyranoside; Cosmosiin; Apigetrin	Reactive Oxygen Species	Cancer
Apigenin-7-glucoside (Apigenin-7-O-β-D-glucopyranoside) exhibits significant anti-proliferative and antioxidant activity and scavenges reactive oxygen species (ROS) .

HY-B1106

Tetrahydroxyquinone Tetrahydroxy-1,4-benzoquinone; Tetrahydroxybenzoquinone	Reactive Oxygen Species Apoptosis	Cancer
Tetrahydroxyquinone (Tetrahydroxy-1,4-benzoquinone), a primitive anticataract agent, is a redox active benzoquinone. Tetrahydroxyquinone can take part in a redox cycle with semiquinone radicals, leading to the formation of reactive oxygen species (ROS) .

HY-B1106A

Tetrahydroxyquinone monohydrate Tetrahydroxy-1,4-benzoquinone monohydrate; Tetrahydroxybenzoquinone monohydrate	Reactive Oxygen Species Apoptosis	Cancer
Tetrahydroxyquinone monohydrate (Tetrahydroxy-1,4-benzoquinone monohydrate), a primitive anticataract agent, is a redox active benzoquinone. Tetrahydroxyquinone monohydrate can take part in a redox cycle with semiquinone radicals, leading to the formation of reactive oxygen species (ROS) .

HY-147795

Nampt-IN-8	NAMPT Apoptosis Reactive Oxygen Species	Cancer
Nampt-IN-8 (Compound 10d) is an NAMPT inhibitor with an IC₅₀ of 0.183 μM. Nampt-IN-8 is also a relatively good NQO1 substrate. Nampt-IN-8 induces cell apoptosis and *ROS* .

HY-N11887

Linocinnamarin	Reactive Oxygen Species	Inflammation/Immunology
Linocinnamarin is a nature product that could be isolated from Fragaria ananassa Duch. Linocinnamarin has anti-inflammatory activity. Linocinnamarin inhibits antigen-stimulated elevation of intracellular free Ca ²⁺ concentration and reactive oxygen species (ROS) .

HY-163862

PPARα agonist 3	PPAR Reactive Oxygen Species	Inflammation/Immunology
PPARα agonist 3 (Compound A229) is a PPARα agonist (EC₅₀: 590 nM). PPARα agonist 3 inhibits TBHP or 4-HNE (HY-113466)-induced production of ROS .

HY-N2693

6,8-Diprenylorobol	Apoptosis Reactive Oxygen Species Caspase Akt ERK JNK p38 MAPK Bcl-2 Family	Cancer
6,8-Diprenylorobol, a prenylated isoflavone, is a nature product that could be isolated from the leaves of Cudrania tricuspidata. 6,8-Diprenylorobol antiproliferative effect and induces apoptosis through activation of p53 and generation of ROS .

HY-122311

Orniplabin SMTP-7	Reactive Oxygen Species	Neurological Disease Inflammation/Immunology
Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits *ROS* .

Cat. No.	Product Name

HY-L075

Anti-Lung Cancer Compound Library

1,933 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1,933 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-W015913

Sodium 2-oxopropanoate 5+ Cited Publications Sodium pyruvate	Cell Assay Reagents
Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

HY-W015913R

Sodium 2-oxopropanoate (standard) 4 Publications Verification	Biochemical Assay Reagents
Sodium 2-oxopropanoate (Standard) is the analytical standard of Sodium 2-oxopropanoate. This product is intended for research and analytical applications. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7798

Pennogenin	Structural Classification Natural Products Liliaceae Classification of Application Fields Source classification Trillium tschonoskii Maxim. Plants Inflammation/Immunology Disease Research Fields	Reactive Oxygen Species
Pennogenin is a bioactive component which can be isolated from T. govanianum rhizomes. Pennogenin exhibits significant in vitro inhibitory effect on release of ROS .

HY-W015913

Sodium 2-oxopropanoate Maximum Cited Publications 9 Publications Verification Sodium pyruvate	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Reactive Oxygen Species Endogenous Metabolite
Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

HY-N0578

Apigenin 7-glucoside 3 Publications Verification Apigenin-7-O-β-D-glucopyranoside; Cosmosiin; Apigetrin	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Dendranthema morifolium (Ramat.) Tzvel. Phenols Polyphenols Plants Compositae Disease Research Fields Cancer	Reactive Oxygen Species
Apigenin-7-glucoside (Apigenin-7-O-β-D-glucopyranoside) exhibits significant anti-proliferative and antioxidant activity and scavenges reactive oxygen species (ROS) .

HY-W015913R

Sodium 2-oxopropanoate (standard) 4 Publications Verification	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reactive Oxygen Species Endogenous Metabolite
Sodium 2-oxopropanoate (Standard) is the analytical standard of Sodium 2-oxopropanoate. This product is intended for research and analytical applications. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

HY-N11887

Linocinnamarin	Structural Classification Natural Products Source classification Rosaceae Plants Fragaria × ananassa Duch.	Reactive Oxygen Species
Linocinnamarin is a nature product that could be isolated from Fragaria ananassa Duch. Linocinnamarin has anti-inflammatory activity. Linocinnamarin inhibits antigen-stimulated elevation of intracellular free Ca ²⁺ concentration and reactive oxygen species (ROS) .

HY-N2693

6,8-Diprenylorobol	Structural Classification Flavonoids Source classification Maclura tricuspidata Carriere Plants Moraceae Isoflavones	Apoptosis Reactive Oxygen Species Caspase Akt ERK JNK p38 MAPK Bcl-2 Family
6,8-Diprenylorobol, a prenylated isoflavone, is a nature product that could be isolated from the leaves of Cudrania tricuspidata. 6,8-Diprenylorobol antiproliferative effect and induces apoptosis through activation of p53 and generation of ROS .

HY-N1306

Sideroxylin	Infection Eucalyptus saligna Flavonoids Classification of Application Fields Flavones Source classification Phenols Polyphenols Myrtaceae Plants Disease Research Fields	Bacterial Reactive Oxygen Species Apoptosis
Sideroxylin is a C-methylated flavone isolated from Callistemon lanceolatus and exerts antimicrobial activity against *Staphylococcus aureus. Sideroxylin inhibits ovarian cancer cell proliferation and induces apoptosis, causing DNA fragmentation, depolarization of the mitochondrial membrane, the generation of reactive oxygen species (ROS)* .

HY-N0578R

Apigenin 7-glucoside (Standard)	Structural Classification Flavonoids Flavones Source classification Dendranthema morifolium (Ramat.) Tzvel. Phenols Polyphenols Plants Compositae	Reactive Oxygen Species
Apigenin 7-glucoside (Standard) is the analytical standard of Apigenin 7-glucoside. This product is intended for research and analytical applications. Apigenin-7-glucoside (Apigenin-7-O-β-D-glucopyranoside) exhibits significant anti-proliferative and antioxidant activity and scavenges reactive oxygen species (ROS) .

Cat. No.	Compare	Product Name	Species	Source

HY-P702714

	ROS1 Protein, Human (sf9, His) ROS1; ROS proto-oncogene 1, receptor tyROSine kinase; ROS; MCF3; c-ROS-1	Human	Sf9 insect cells
	ROS1 Protein, Human (sf9, His) is the recombinant human-derived ROS1, expressed by Sf9 insect cells , with His labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition ^[1] .

HY-12678S1

Entrectinib-d8

Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC₅₀ values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice ^[1] .

HY-W015913S

Sodium 2-oxopropanoate-13C3
Sodium 2-oxopropanoate- ¹³C₃ is the ¹³C-labeled Sodium 2-oxopropanoate. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS[1][2].

HY-B0847S

Propiconazole-d7

Propiconazole-d₇ is the deuterium labeled Propiconazole. Propiconazole is a broad-spectrum triazole fungicide that inhibits the conversion of lanosterol to ergosterol, leading to fungal cell membrane disruption. Propiconazole inhibits S. cerevisiae, but not rat liver, microsomal cytochrome P450 (IC50s=0.04 and >200 µM, respectively). Propiconazole inhibits the growth of T. deformans and R. stolonifer (ED50s=0.073 and 4.6 µg/mL, respectively). Propiconazole increases production of reactive oxygen species (ROS)[1].

HY-12678S

Entrectinib-d4

Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib (HY-12678). Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice ^[1] .

HY-50878AS

Crizotinib-d9 hydrochloride

Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition ^[1] .

Cat. No.	Product Name		Classification

HY-159147

SIAIS039		Azide
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC₅₀s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) ^[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ROS1

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products